Qingdao Huanghai Biological Pharmaceutical Sets Up Sodium Alginate Production Base
This article was originally published in PharmAsia News
Qingdao Huanghai Biological Pharmaceutical, a subsidiary of Qingdao Huanghai Pharmaceutical, recently hosted a ground-breaking ceremony for its medical sodium alginate production project in Jiaozhou city, Qingdao. With a total investment of RMB 300 million, the 66,072-square-meter facility began construction in February and is scheduled for operation at year end. The first phase, with RMB 100 million funding, will involve setting up a raw pharmaceutical materials production workshop, office buildings, warehouses and auxiliary facilities. Huanghai Biological will mainly produce azelnidipine and sodium alginate, and target a production value of RMB 1 billion for sodium alginate within three years. Analysts see the move significant since the plant represents China's first sodium alginate manufacturing facility for medical use, indicating the market potential for local biopharmaceutical industry development. (Click here for more - Chinese Language)
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban
The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.